AllianceBernstein
RXRX icon

AllianceBernstein’s Recursion Pharmaceuticals RXRX Stock Holding History

AllianceBernstein’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45M Buy
472,284
+14,780
+3% +$49.2K ﹤0.01% 2205
2026
Q1 		$1.87M Buy
457,504
+96,130
+27% +$371K ﹤0.01% 2044
2025
Q4 		$1.48M Sell
361,374
-508
-0.1% -$2.52K ﹤0.01% 2160
2025
Q3 		$1.77M Buy
361,882
+508
+0.1% +$2.67K ﹤0.01% 2075
2025
Q2 		$1.83M Buy
361,374
+108,860
+43% +$535K ﹤0.01% 1983
2025
Q1 		$1.34M Buy
252,514
+9,300
+4% +$67.8K ﹤0.01% 2100
2024
Q4 		$1.64M Buy
243,214
+25,920
+12% +$174K ﹤0.01% 2071
2024
Q3 		$1.43M Hold
217,294
– – ﹤0.01% 2141
2024
Q2 		$1.63M Buy
217,294
+73,250
+51% +$639K ﹤0.01% 2068
2024
Q1 		$1.44M Sell
144,044
-66,872
-32% -$745K ﹤0.01% 2086
2023
Q4 		$2.08M Buy
210,916
+47,794
+29% +$341K ﹤0.01% 1915
2023
Q3 		$1.25M Sell
163,122
-145,540
-47% -$1.45M ﹤0.01% 2125
2023
Q2 		$2.31M Hold
308,662
– – ﹤0.01% 1829
2023
Q1 		$2.06M Sell
308,662
-81,943
-21% -$650K ﹤0.01% 1857
2022
Q4 		$3.01M Sell
390,605
-2,846,739
-88% -$27.9M ﹤0.01% 1671
2022
Q3 		$34.4M Sell
3,237,344
-363,616
-10% -$3.68M 0.02% 656
2022
Q2 		$29.3M Buy
3,600,960
+220,242
+7% +$1.47M 0.01% 736
2022
Q1 		$24.2M Buy
3,380,718
+504,899
+18% +$5.37M 0.01% 848
2021
Q4 		$49.3M Buy
2,875,819
+1,236,478
+75% +$23.3M 0.02% 626
2021
Q3 		$37.7M Buy
1,639,341
+339,419
+26% +$9.62M 0.01% 707
2021
Q2 		$47.4M Buy
+1,299,922
New +$38.5M 0.02% 634

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AllianceBernstein's RXRX Position: Q2 2026 in Review

AllianceBernstein increased its Recursion Pharmaceuticals (RXRX) stake by 3.2% in Q2 2026, buying an estimated $49.2K and bringing the position to 472,284 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2205.

AllianceBernstein first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $49.3M in Q4 2021. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • AllianceBernstein held 472,284 shares of Recursion Pharmaceuticals worth $1.45M as of Q2 2026.
  • AllianceBernstein bought 14,780 Recursion Pharmaceuticals shares in Q2 2026, an estimated $49.2K.
  • Recursion Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2205 holding.
  • AllianceBernstein first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • AllianceBernstein's Recursion Pharmaceuticals position peaked at $49.3M in Q4 2021.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.